Prospective study of mutant frequencies at the hprt and T-cell receptor gene loci in pediatric cancer patients during chemotherapy

Cancer Epidemiology Biomarkers and Prevention

Volumn 7, Issue 8, 1998, Pages 711-717

  Sawada, Machiko ^a   Kubota, Masaru ^a   Lin, Ying Wei ^a   Watanabe, Ken Ichiro ^a   Koishi, Seiji ^a   Usami, Ikuya ^a   Akiyama, Yuichi ^a   Matsumura, Takafumi ^b   Furusho, Kenshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; HODGKIN DISEASE; HUMAN; INFANT; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; HODGKIN DISEASE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INFANT; KIDNEY NEOPLASMS; MALE; MUTATION; NEUROBLASTOMA; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; WILMS TUMOR;

EID: 0031828959     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Smith, M B., Xue, H., Strong, L., Takahashi, H , Jaffe, N., Ried, H., Zietz, H., Andrassy, H., and Andrassy, R. J. Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J. Pediatr. Surg., 28. 1342-1349, 1993
2. Pui, C. H., Ribeiro, R C., Hancock, M. L., Rivera, G. K., Evans, W E., Raimondi, S C., Head, D. R., Behm, F. G., Mahmoud, M H., Sandland, J. T , and Christ, W. M. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia N Engl. J Med , 325: 1682-1687,1991.
3. Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M , Bunin, G., FossatiBellani, F., and Meadows, A. T. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med., 334: 745-751, 1996
4. Tucker, M. A., Meadows, A. T., Boice, J. D., Jr, Stovall, M, Oberlin, O , Stone, B. J., Birch, J., Voute, P. A. Hoover, R. N., and Fraumeni, J F., Jr Leukemia after therapy with alkylating agents for childhood cancer J. Natl Cancer Inst., 78: 459-464, 1987.
5. Cole, J , and Skopek, T. R Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. Mutai. Res., 304: 33-105, 1994
6. Hakoda, M , Akiyama, M., Kyoizumi, S., Awa, A A., Yamakido, M., and Otake, M. Increased somatic cell mutant frequency in atomic bomb survivors. Mutat. Res., 201: 39-48, 1988
7. Cole, I., Arlett, C F., Green, M. H. L., James, S. E , Henderson, L., Cole, H , Sala-Trepat, M , Benzi, R., Price, M. L., and Bridges, B A. Measurement of mutant frequency to 6-thioguanine resistance in circulating T-lymphocytes for human population monitoring. In: G Jolies and A Cordier (eds.), New Trends in Genetic Risk Assessment, pp 175-203. London: Academic Press, 1989.
8. Cole, J., Arlett, C. F., Norris, P. G., Stephens, G., Waugh, A. P. W., Beare, D. M., and Green, M H. L. Elevated hprt mutant frequency in circulating T-lymphocytes of xeroderma pigmentosum patients. Mutat. Res., 273: 171-178, 1992
9. Nicklas, J. A , Falta, M. T., Hunter, T. C., O'Neill, J. P , Jacobson-Kram, D., Williams, J. R., and Albertini, R J Molecular analysis of in vivo hprt mutations in human T lymphocytes V Effects of total body irradiation secondary to radioimmunoglobulin therapy (RIT). Mutagenesis, 5: 461-468, 1990.
10. + T cells J. Exp. Med., 171. 1981-1999, 1990.
11. Kyoizumi, S., Umeki, S., Akiyama, M , Hirai, Y , Kusunoki, Y , Nakamura, N., Endoh, K., Konishi, J., Sasaki, M. S , Mon, T , Fujita, S., and Cologne, J. B. Frequency of mutant T lymphocytes defective in the expression of the T-cell antigen receptor gene among radiation-exposed people. Mutat. Res, 265 173-180, 1992
12. Dempsey, J L., Seshadri, R. S., and Morley, A. A. Increased mutation frequency following treatment with cancer chemotherapy Cancer Res., 45: 2873-2877 1985.
13. Branda, R. F., O'Neill, J. P., Sullivan, L M , and Albertini, R. J. Factors influencing mutation at the hprt locus in T-lymphocytes: women treated for breast cancer. Cancer Res., 51: 6603-6607, 1991.
14. Bigbee, W. L., Wyrobek, A. J., Langlois, R G., Jensen, R. H., and Everson, R. B The effect of chemotherapy on the in vivo frequency of glycophorin A "null" variant erythrocytes. Mutat. Res., 240: 165-175, 1990.
15. Hirota, H., Kubota, M., Hashimoto, H., Adachi, S., Matsubara, K , Kuwakado, K., Akiyama, Y., Tsutsui, T., and Mikawa, H. Analysis of hprt gene mutation following anti-cancer treatment in pediatric patients with acute leukemia. Mutat. Res , 319. 113-120, 1993.
16. Hirota, H , Kubota, M , Adachi, S., Okuda, A., Lin, Y W., Bessho, R., Wakazono, Y., Matsubara, K., Kuwakado, K., Akiyama, Y., and Tsutsui, T. Somatic mutations at T-cell antigen receptor and glycophorin A loci in pediatric leukemia patients following chemotherapy: comparison with HPRT locus mutation. Mutat. Res., 315: 95-103, 1994
17. Perera, F. P, Motzer, R. J., Tang, D , Reed, E , Parker, R , Warburton, D , O'Neil, P., Albertini, R., Bigbee, W. L., Jensen, R. H., Santella, R., Tsai, W. Y., Simon-Cereijido, G., Randall, C., and Bosl. G. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res., 52: 3558-3565, 1992.
18. Tates, A. D , van Dam, F. J., Natarajan, A T., Zwinderman, A. H , and Osanto. S Frequencies of HPRT mutants and micronuclei in lymphocytes of cancer patients under chemotherapy: a prospective study. Mutat Res., 307. 293-306, 1994.
19. Kamaoukhova, L., Moffat, J., Martins, H., and Glickman, B. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy Cancer Res., 57: 4393-4407, 1997
20. Sawada, M., Kubota, M , Lin, Y W., Watanabe, K., Koishi, S., Usami, I, Akiyama, Y , Matsumura, T., and Furusho, K. Evaluation of mutant frequencies at hprt and T-cell receptor loci in pediatric cancer patients before treatment. Mutat Res., 397: 337-343, 1998.
21. Albertini, R. J., Castle, K. L., and Borcherding, W R T-cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood Proc. Natl. Acad. Sci USA, 79: 6617-6621, 1982
22. Morley, A A , Trainor, K J , Seshadri, R , and Ryall, R. G Measurement of in vivo mutations in human lymphocytes. Nature (Lond.), 302: 155-156, 1983.
23. Hakoda, M., Akiyama, M , Kyoizumi, S., Kobuke, K , Awa, A. A , and Yamakido, M. Measurement of in vivo HGPRT-deficient mutant cell frequency using a modified method for cloning human peripheral blood T-lymphocytes. Mutat. Res., 197: 161-169, 1988.
24. de Boer, J. G., Curry, J. D., and Glickman, B. W. A fast and simple method to determine the clonal relationship among human T-cell lymphocytes. Mutat Res., 288. 173-180, 1993.
25. Furth, E. E , Thilly, W. G., Penman, B. W., Liber, H L., and Rand, W M. Quantitative assay for mutation in diploid human lymphoblasts using microtiter plates Anal. Biochem., 110: 1-8, 1981
26. Malkin, D , Jolly, K. W., Barbier, N , Look, A T., Friend, S. H., Gebhardt, M. C., Anderson, T. I., Borresen, A. L , Li, F. P., Garber, J., and Strong, L G. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N. Engl. J. Med , 326: 1309-1315, 1992.
27. Rubin, C. M., Arthur, D. C., Woods, W. G., Lange, B. J., Nowell, P. C., Rowley, J. D., Nachman, J., Bostrom, B., Baum, E S., Suarez, C R., Shah, N. R , Morgan, E , Maurer, H. S., McKenzie, S. E., Larson, R. A., and Le Beau, M. M. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood, 78: 2982-2988, 1991.
28. Loeb, L A., and Christians, F. C. Multiple mutations in human cancers. Mutat. Res., 350. 279-286, 1996.
29. Heddle, J, A., and Swiger, R. R. Risk estimation from somatic mutation assays. Mutat. Res., 365: 107-117, 1996.
30. Bartsch, H , and Malaveille, C. Screening assays for carcinogenic agents and mixtures; an appraisal based on data in the IARC Monograph series. IARC Sci Publ., 104: 65-74, 1990
31. Caggana, M., Liber, H L , Mauch, P. M., Coleman, C N., and Kelsey, K T. In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients. Environ. Mol. Mutagen., 18. 6-13, 1991.
32. Shulman, L. N. The biology of alkylating-agent cellular injury. Hematol Oncol Clin. N Am , 7: 325-335, 1993.
33. Sanderson, B. J., and Shield, A J. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat. Res , 355: 41-57, 1996.
34. Hashimoto, H., Chatterjee, S., and Berger, N A. Mutagenic activity of topoisomerase I inhibitors. Clin. Cancer Res , 1: 369-376, 1995.
35. Ferguson, L R., and Baguley, B. C. Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Mutat. Res , 355. 91-101, 1996.
36. Chow, S. C , Snowden, R , Orrenius, S., and Cohen, G M. Susceptibility of different subsets of immature thymocytes to apoptosis. FEBS Lett, 408. 141-146, 1997
37. Usami, I , Kubota, M., Bessho, R., Kataoka, A., Koishi, S., Watanabe, K., Sawada, M., Lin, Y W., Akiyama, Y., and Furusho, K Role of protein tyrosine phosphorylation in etoposide-induced apoptosis and NF-κB activation. Biochem. Pharmacol , 55: 185-191, 1998.
38. Muscarella, D E., Rachlinski, M. K., Sotinadis, J., and Bloom, S. E. Contribution of gene-specific lesions. DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells. Exp. Cell Res , 238 155-167, 1998.
39. Maraschin, J., Dutrillaux, B., and Aurias, A. Chromosome aberrations by etoposide (VP-16) are not random. Int. J. Cancer, 46: 808-812, 1990
40. Mott, M. G., Boyse, J., Hewitt, M , and Radford, M. Do mutations at the glycophorin A locus in patients treated for childhood Hodgkin's disease predict secondary leukemia? Lancet, 343: 828-829, 1994.
41. Boyse, J., Hewitt, M., and Mott, M. G Glycophorin A mutations and risk of secondary leukemia in patients treated for childhood acute lymphoblastic leukemia. Br J. Haematol, 93. 117-124, 1996.